Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 670

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Open access
Pötter, Richard, Tanderup, Kari, Schmid, Maximilian Paul, Jürgenliemk-Schulz, Ina, Haie-Meder, Christine, Fokdal, Lars Ulrik, Sturdza, Alina Emiliana, Hoskin, Peter, Mahantshetty, Umesh, Segedin, Barbara, Bruheim, Kjersti, Huang, Fleur, Rai, Bhavana, Cooper, Rachel, van der Steen-Banasik, Elzbieta, Van Limbergen, Erik, Pieters, Bradley Rumwell, Tan, Li-Tee, Nout, Remi Abubakar, De Leeuw, Astrid Agatha Catharina, Ristl, Robin, Petric, Primoz, Nesvacil, Nicole, Kirchheiner, Kathrin, Kirisits, Christian, Lindegaard, Jacob Christian, Chargari, Cyrus, Dumas, Isabelle, Lowe, Gerry, Swamidas, Jamema, Hudej, Robert, Paulsen Hellebust, Taran, Menon, Geetha, Oinam, Arun S., Bownes, Peter, Christiaens, Melissa, De Brabandere, Marisol, Janssen, Hilde, Oosterveld, Bernard, Koedooder, Kees, Langeland Marthinsen, Anne Beate, Sundset, Marit, Whitney, Diane, Ketelaars, Martijn, Lutgens, Ludy C.H.W., Reinniers, Brigitte, Mora, Itxa, Villafranca, Elena, Antal, Gergely, Hadjiev, Janaki, Bachand, Francois, Batchelar, Deidre, Erickson, Beth, Rownd, Jason, Jacobson, Geraldine, Kim, Yusung, Anttila, Maarit, Palmgren, Jan-Erik, An, Jusheng, Assenholt, Marianne Sanggaard, Banerjee, Susovan, Bentzen, Sören, Berger, Thomas, Dankulchai, Pittaya, Diendorfer, Tamara, Dilworth, Ian, Dimopoulos, Johannes, Dörr, Elke, Ecker, Stefan, Federico, Mario, Fidarova, Elena, Fortin, Israel, Georg, Petra, Gora, Joanna, Hegazy, Neamat, Jastaniyah, Noha, Jensen, Nina Boje Kibsgaard, Liederer, Thomas, Majercakova, Katarina, Misimovic, Dragan, Motisi, Laura, Najjari Jamal, Dina, Nkiwane, Karen, Schwartz-Vittrup, Anders, Serban, Monica, Smet, Stephanie, Spampinato, Sofia, Trnkova, Petra, Valgma, Margit, Westerveld, Henrike, Wong, Joyce Siu Yu, Yoshida, Kenji · 2021 · The Lancet Oncology

Abstract

BACKGROUND The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT. METHODS EMBRACE-I was a prospective, observational, multicentre cohort study. Data from patients from 24 centres in Europe, Asia, and North America were prospectively collected. The inclusion criteria were patients older than 18 years, with biopsy-proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, The International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA disease or FIGO stage IVB disease restricted to paraaortic lymph metastasis below the L1-L2 interspace, suitable for curative treatment. Treatment consisted of chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2, 5-6 cycles, 1 day per cycle, plus 45-50 Gy external-beam radiotherapy delivered in 1·8-2 Gy fractions) followed by MRI-based IGABT. The MRI-based IGABT target volume definition and dose reporting was according to Groupe Européen de Curiethérapie European Society for Radiation Oncology recommendations. IGABT dose prescription was open according to institutional practice. Local control and late morbidity were selected as primary endpoints in all patients available for analysis. The study was registered with ClinicalTrials.gov, NCT00920920. FINDINGS Patient accrual began on July 30, 2008, and closed on Dec 29, 2015. A total of 1416 patients were registered in the database. After exclusion for not meeting patient selection criteria before treatment, being registered but not entered in the database, meeting the exclusion criteria, and being falsely excluded, data from 1341 patients were available for analysis of disease and data from 1251 patients were available for assessment of morbidity outcome. MRI-based IGABT including dose optimisation was done in 1317 (98·2%) of 1341 patients. Median high-risk clinical target volume was 28 cm3 (IQR 20-40) and median minimal dose to 90% of the clinical target volume (D90%) was 90 Gy (IQR 85-94) equi-effective dose in 2 Gy per fraction. At a median follow-up of 51 months (IQR 20-64), actuarial overall 5-year local control was 92% (95% CI 90-93). Actuarial cumulative 5-year incidence of grade 3-5 morbidity was 6·8% (95% CI 5·4-8·6) for genitourinary events, 8·5% (6·9-10·6) for gastrointestinal events, 5·7% (4·3-7·6) for vaginal events, and 3·2% (2·2-4·5) for fistulae. INTERPRETATION Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies. FUNDING Medical University of Vienna, Aarhus University Hospital, Elekta AB, and Varian Medical Systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30753-1

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 670

Metadata

Authors
Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A. E., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Tan, L.-T., Nout, R. A., De Leeuw, A. A. C., Ristl, R., Petric, P., Nesvacil, N., Kirchheiner, K., Kirisits, C., Lindegaard, J. C., Chargari, C., Dumas, I., Lowe, G., Swamidas, J., Hudej, R., Paulsen Hellebust, T., Menon, G., Oinam, A. S., Bownes, P., Christiaens, M., De Brabandere, M., Janssen, H., Oosterveld, B., Koedooder, K., Langeland Marthinsen, A. B., Sundset, M., Whitney, D., Ketelaars, M., Lutgens, L. C. H. W., Reinniers, B., Mora, I., Villafranca, E., Antal, G., Hadjiev, J., Bachand, F., Batchelar, D., Erickson, B., Rownd, J., Jacobson, G., Kim, Y., Anttila, M., Palmgren, J.-E., An, J., Assenholt, M. S., Banerjee, S., Bentzen, S., Berger, T., Dankulchai, P., Diendorfer, T., Dilworth, I., Dimopoulos, J., Dörr, E., Ecker, S., Federico, M., Fidarova, E., Fortin, I., Georg, P., Gora, J., Hegazy, N., Jastaniyah, N., Jensen, N. B. K., Liederer, T., Majercakova, K., Misimovic, D., Motisi, L., Najjari Jamal, D., Nkiwane, K., Schwartz-Vittrup, A., Serban, M., Smet, S., Spampinato, S., Trnkova, P., Valgma, M., Westerveld, H., Wong, J. S. Y., & Yoshida, K.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-04
Volume
22
Issue
4
Pages
538-547
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3142845014
Cited by
670
References
13
FWCI
80.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30753-1
The paper
Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A. E., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Tan, L.-T., Nout, R. A., . . . Yoshida, K. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30753-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.